Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of S-337395 in Healthy Adults
jRCT2031230033Phase 1Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing S-337395 with Placebo (2 arms). Primary endpoints: Safety and tolerability (adverse events), Physical examination findings and 4 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
S-337395
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031230033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230033.